PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NICE recommend’s use of Leo Pharma’s Adtralza

The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment.

The National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document recommending Leo Pharma’s Adtralza (tralokinumab), Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for use within NHS England and Wales.

The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment, if the disease has not responded to at least one systemic immunosuppressant or if that initial treatment was unsuitable.

The development comes at a time when atopic dermatitis affects approximately 3.5% of adults across Europe.

Adtralza is the first human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine in adult patients with uncontrolled moderate-to-severe atopic dermatitis. It is available in a prefilled syringe for subcutaneous injection and can be used with or without topical corticosteroids.

“NICE’s decision to recommend tralokinumab is an important step for those living with moderate-to-severe atopic dermatitis. We are delighted that this recommendation will give those living with the condition in England and Wales access to a new treatment option,” explained Sarah Kleinpeter, vice president and general manager of the UK and Ireland at LEO Pharma.

“This approval represents the latest innovation from LEO Pharma as we continue to support people living with skin conditions. Thank you to all the LEO Pharma employees and our partners, as well as the clinicians and patient organisations who have worked so hard to support this process for patients,” she added.

“Atopic dermatitis patients often have individual, complex needs. This recommendation offers significant new treatment options for atopic dermatitis patients and is an essential step in improving patient experience and quality of life in England and Wales,” concluded Professor Anthony Bewley, consultant dermatologist at Barts Health NHS Trust.

Adtralza was initially approved by the European Commission and the Medicines and Healthcare products Regulatory Agency in 2021.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026